140 results
8-K
TVTX
Travere Therapeutics Inc
4 Dec 23
Cost Associated with Exit or Disposal Activities
4:10pm
. The Company expects that the majority of the restructuring charges will be incurred in Q4 2023 and that the implementation of the workforce reduction
8-K
EX-99.1
2fgst
22 May 23
Departure of Directors or Certain Officers
4:30pm
8-K/A
EX-10.1
b2jcexr
17 Aug 22
Departure of Directors or Certain Officers
5:20pm
8-K
EX-99.1
tg776g0e0
12 May 22
Departure of Directors or Certain Officers
5:26pm
8-K
EX-1.1
035r41u
11 Mar 22
Travere Announces Proposed Convertible Senior Notes Offering
4:06pm
8-K
EX-4.2
8pcatu1wryuhbc3
11 Mar 22
Travere Announces Proposed Convertible Senior Notes Offering
4:06pm
424B5
o6qo d4t3g53
9 Mar 22
Prospectus supplement for primary offering
4:20pm